BioCryst Pharmaceuticals is trading at $7.40, down 10.74% in pre-market, with the reason for the decline unclear. - No clear company-specific announcement explaining the October 9 pre-market decline was found; recent coverage concerns an October 5 scientific advisory board announcement, not a new catalyst for this move. - Major U.S. indices were higher, so broad-market direction does not clearly explain the drop. - Pre-market trading activity details were unavailable in the provided price context and retrieved coverage.